SEP 16, 2015 07:00 AM PDT

Editas Medicine, Creating a novel class of genome editing therapeutics

  • Chief Technology Officer, Editas
      Vic Myer is the chief technology officer for Editas Medicine, a leading genome editing company bringing specific expertise in CRISPR/Cas9 and TALENs technologies. Prior to Editas, Vic served as executive director and Cambridge site head for the developmental and molecular pathways department at the Novartis Institutes for Biomedical Research Incorporated (NIBR), where he also served as a research investigator, led the high throughput biology team and oversaw the target discovery technologies platform. Vic was also a founding scientist and group leader at Akceli, Inc., a venture-backed systems-biology company focusing on commercialization of a high-throughput cell-based micro-array technology, served as senior scientist for Millennium Pharmaceuticals and held various roles at Corning, Inc. Vic received his B.S. in biology (biochemistry) from Cornell University and his Ph.D. in molecular biophysics and biochemistry from Yale University.

    Genome editing technologies, including the CRISPR/Cas9 system, allow for precise and corrective molecular modifications to treat the underlying cause of genetic diseases. Editas Medicine is developing CRISPR/Cas9-based therapeutics across abroad range of indications. This presentation will focus on Editas'approach to CRISPR technology optimization within the context of specific ex vivo and in vivo therapeutic applications

    Show Resources
    Loading Comments...